StroesESThompsonPDCorsiniA, et al; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012-1022.
2.
HeeschenCHammCWLaufsU, et al; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105(12):1446-1452.
3.
RosensonRSMillerKBaylissM, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179-186.
4.
WardenBAGuytonJRKovacsAC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19-39.
5.
BackesJMVeneroCVGibsonCA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008;42(3):341-346.
6.
CheeleyMKSaseenJJAgarwalaA, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361-375.
7.
BardoliaCAminNSTurgeonJ.Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol. Front Cardiovasc Med. 2021;8:789931. doi:10.3389/ fcvm.2021.789931
8.
WritingCommitteeLloyd-JonesDMMorrisPB, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardio. 2022;80(14):1366-1418.
9.
CannonCPBlazingMAGiuglianoRP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397.
10.
NissenSELincoffAMBrennanD, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353-1364.
11.
LaufsUBanachMManciniGBJ. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662. doi:10.1161/JAHA.118.011662
12.
American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes — 2024. Diabetes Care. 2024;47(supple 1):S179-S218.
13.
SabatineMSGiuglianoRPKeechAC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722.
14.
SchwartzGGStegPGSzarekM, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107.
15.
StroesEColquhounDSullivanD, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-2548.
16.
MoriartyPMThompsonPDCannonCP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758-769.
17.
RayKKWrightRSKallendD, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med2020;382:1507-1519.
18.
WrightRSKallendDRaalFJ, et al. Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11). Eur Heart J. 2020;41:ehaa946.3009. doi:10.1093/ehjci/ehaa946.3009
